As we enter what may be the “new normal,” Dexcom’s CEO bets the company can pave the way in continuous glucose monitoring.
Dexcom (NSDQ:DXCM), like any company seeking to innovate, remains in a state of perpetual forward motion.
That’s the way chair, president & CEO Kevin Sayer views it, anyway. As the company looks toward the future, the G7 continuous glucose monitor is the next big thing.
San Diego–based Dexcom’s latest iteration of its CGM system — building on the G6, which first won FDA approval in 2018 — has inspired plenty of optimism, both within the ranks of Dexcom and likely among customers, too.
Get the full story at our sister site, Drug Delivery Business News.
